524 related articles for article (PubMed ID: 19800535)
21. Effects on choroidal neovascularization after anti-VEGF Upload using intravitreal ranibizumab, as determined by spectral domain-optical coherence tomography.
Framme C; Panagakis G; Birngruber R
Invest Ophthalmol Vis Sci; 2010 Mar; 51(3):1671-6. PubMed ID: 19875667
[TBL] [Abstract][Full Text] [Related]
22. Early clinical experience with ranibizumab for occult and minimally classic neovascular membranes in age-related macular degeneration.
Mantel I; Zografos L; Ambresin A
Ophthalmologica; 2008; 222(5):321-3. PubMed ID: 18617755
[TBL] [Abstract][Full Text] [Related]
23. Intravitreal ranibizumab may induce retinal arteriolar vasoconstriction in patients with neovascular age-related macular degeneration.
Papadopoulou DN; Mendrinos E; Mangioris G; Donati G; Pournaras CJ
Ophthalmology; 2009 Sep; 116(9):1755-61. PubMed ID: 19560206
[TBL] [Abstract][Full Text] [Related]
24. Ranibizumab: new drug. Macular degeneration: second-line use due to risks.
Prescrire Int; 2008 Feb; 17(93):3-6. PubMed ID: 18354841
[TBL] [Abstract][Full Text] [Related]
25. [Subretinal hemorrhage after intravitreal injection of anti-VEGF for age-related macular degeneration: a retrospective study].
Baeteman C; Hoffart L; Galland F; Ridings B; Conrath J
J Fr Ophtalmol; 2009 May; 32(5):309-13. PubMed ID: 19769866
[TBL] [Abstract][Full Text] [Related]
26. Computerized model of cost-utility analysis for treatment of age-related macular degeneration.
Fletcher EC; Lade RJ; Adewoyin T; Chong NV
Ophthalmology; 2008 Dec; 115(12):2192-8. PubMed ID: 18930556
[TBL] [Abstract][Full Text] [Related]
27. Implementation studies of ranibizumab for neovascular age-related macular degeneration.
Bloch SB
Acta Ophthalmol; 2013 Nov; 91 Thesis7():1-22. PubMed ID: 24206851
[TBL] [Abstract][Full Text] [Related]
28. [Cost-utility analysis of ranibizumab (Lucentis) in neovascular macular degeneration].
Neubauer AS; Holz FG; Schrader W; Back EI; Kühn T; Hirneiss C; Kampik A
Klin Monbl Augenheilkd; 2007 Sep; 224(9):727-32. PubMed ID: 17846963
[TBL] [Abstract][Full Text] [Related]
29. Incidence of new choroidal neovascularization in fellow eyes of patients treated in the MARINA and ANCHOR trials.
Barbazetto IA; Saroj N; Shapiro H; Wong P; Ho AC; Freund KB
Am J Ophthalmol; 2010 Jun; 149(6):939-946.e1. PubMed ID: 20378094
[TBL] [Abstract][Full Text] [Related]
30. Ranibizumab for predominantly classic neovascular age-related macular degeneration: subgroup analysis of first-year ANCHOR results.
Kaiser PK; Brown DM; Zhang K; Hudson HL; Holz FG; Shapiro H; Schneider S; Acharya NR
Am J Ophthalmol; 2007 Dec; 144(6):850-857. PubMed ID: 17949673
[TBL] [Abstract][Full Text] [Related]
31. [Treatment of neovascular age-related macular degeneration with Ranibizumab/Lucentis].
Michels S; Rosenfeld PJ
Klin Monbl Augenheilkd; 2005 Jun; 222(6):480-4. PubMed ID: 15973626
[TBL] [Abstract][Full Text] [Related]
32. The role of choroidal hypoperfusion associated with photodynamic therapy in neovascular age-related macular degeneration and the consequences for combination strategies.
Schmidt-Erfurth U; Kiss C; Sacu S
Prog Retin Eye Res; 2009 Mar; 28(2):145-54. PubMed ID: 19272333
[TBL] [Abstract][Full Text] [Related]
33. In vivo three-dimensional imaging of neovascular age-related macular degeneration using optical frequency domain imaging at 1050 nm.
de Bruin DM; Burnes DL; Loewenstein J; Chen Y; Chang S; Chen TC; Esmaili DD; de Boer JF
Invest Ophthalmol Vis Sci; 2008 Oct; 49(10):4545-52. PubMed ID: 18390638
[TBL] [Abstract][Full Text] [Related]
34. Current treatment of age-related macular degeneration.
Zarbin M; Szirth B
Optom Vis Sci; 2007 Jul; 84(7):559-72. PubMed ID: 17632299
[TBL] [Abstract][Full Text] [Related]
35. Responsiveness of NEI VFQ-25 to changes in visual acuity in neovascular AMD: validation studies from two phase 3 clinical trials.
Suñer IJ; Kokame GT; Yu E; Ward J; Dolan C; Bressler NM
Invest Ophthalmol Vis Sci; 2009 Aug; 50(8):3629-35. PubMed ID: 19255158
[TBL] [Abstract][Full Text] [Related]
36. Intravitreal ranibizumab for the primary treatment of choroidal neovascularization secondary to pathologic myopia.
Lai TY; Chan WM; Liu DT; Lam DS
Retina; 2009 Jun; 29(6):750-6. PubMed ID: 19357555
[TBL] [Abstract][Full Text] [Related]
37. [Macular translocation - a therapeutic approach for neovascular macular degeneration in the era of anti-VEGF therapy?].
Ziemssen F; Gelisken F
Klin Monbl Augenheilkd; 2009 Jan; 226(1):31-7. PubMed ID: 19173161
[TBL] [Abstract][Full Text] [Related]
38. Anti-VEGF agents for age-related macular degeneration.
Ozkiris A
Expert Opin Ther Pat; 2010 Jan; 20(1):103-18. PubMed ID: 20021287
[TBL] [Abstract][Full Text] [Related]
39. [Combined therapy in the exsudative age-related macular degeneration (photodynamic therapy and intravitreally-applied ranibizumab)].
Ernest J; Hejsek L; Benesová Z; Ová Z; Remont L; Nemec P
Cesk Slov Oftalmol; 2010 Jul; 66(3):119-23, 126. PubMed ID: 21137472
[TBL] [Abstract][Full Text] [Related]
40. [Frequency of neovascular lesion types in wet age-related macular degeneration].
Gierek-Lapińska A; Wykrota H; Trzciakowski K; Szymkowiak M; Gierek-Ciaciura S
Klin Oczna; 2004; 106(3 Suppl):463-5. PubMed ID: 15636237
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
